Law360, New York (October 31, 2006, 12:00 AM EST) -- Worried about the impact on consumer prices from consolidation in the generic drug industry, the Federal Trade Commission said Tuesday it would approve Watson Pharmaceuticals Inc.’s proposed $1.9 billion acquisition of Andrx Corp., but only if the companies sell off their overlapping drug lines.
The FTC said it would let the deal go through, but only if the companies addressed “competitive problems in the markets for 13 generic drug products.”
Watson will have to end its marketing agreement with Interpharm to market generic ibuprofen tablets, a...
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.